Hosts
Diana Saville
BrainMind
Michael Brotherton
Dragonfly 44 Capital
Presentors
Marcus is CEO of Blackrock Neurotech. He is on the advisory board of various disruptive technology companies including fin-tech Deposit Solutions (US). Marcus has an MPhil from Oxford University and an MA from St. Andrews. He is an entrepreneur focused on innovative technologies and alternative investment markets. In 1999, Marcus helped set up his first start-up, Mondus, a pioneering e-commerce platform. Subsequently, Marcus founded BBI, which advised technology companies on funding, commercialization, and growth strategies. In 2003, he co-founded one of the leading frontier market asset managers in the Middle East. With Blackrock, he is hoping to improve the patient impact as it relates to the final frontier of the human body – the brain. He is all too aware of the limits of his own body when it comes to riding and hiking up and down the Wasatch mountains, but that does not stop him from trying to push that frontier too.
Co-Founder & CEO, Blackrock Neurotech
Dr. Rosenbaum, Stanley Cobb Professor of Psychiatry at Harvard Medical School, chaired the Massachusetts General Hospital Psychiatry Department for 20 years, leading 600 clinicians and researchers, and 150 trainees. At Mass General, he served as Chair of the Executive Committee on Research. He was the 2007 recipient of the C. Charles Burlingame Award for lifetime achievement in psychiatric research and education and the 2016 recipient of the Joseph B. Martin Dean's Leadership Award for the Advancement of Women Faculty for Harvard Medical School. He is Emeritus Fellow of the American College of Neuropsychopharmacology (ACNP). In 2018, he was an Ellis Island Medal of Honor awardee. He was President/Board Chair of the Anxiety and Depression Association of America (ADAA) and served as President and is a Board member of the American Foundation for Suicide Prevention. He served a six-year term as Trustee of the Massachusetts General Hospital and was Trustee of the Partners Healthcare System. He is co-Chair of Development at Mass General. He’s co-authored more than 400 original articles and reviews and edited 20 books. He led longitudinal studies of children at risk for anxiety disorders and depression, which examined behavioral differences, risk factors, longitudinal outcomes, treatment, genetics and brain structure and function of children of parents with mood and anxiety disorders. He is currently directing The Center for Neuroscience of Psychedelics to understand how psychedelics change the brain and to explore novel mechanisms for treatment of psychiatric disorders. He co-founded Psy Therapeutics to advance the discovery of novel drugs for psychiatric and neurologic disorders and is co-founder of Sensorium Therapeutics, Inc. to explore plant derived molecules as leads for novel psychiatric therapeutics.
Dr. Rosenbaum received his undergraduate degree from Yale College in 1969 and his medical degree from Yale School of Medicine in 1973. He completed his residency and fellowship in Psychiatry at Massachusetts General Hospital, Harvard Medical School.
Psychiatrist-in-Chief emeritus
Director Center for Anxiety and Traumatic Stress Disorders, MGH
Jonathan Sporn, MD is a board-certified psychiatrist and seasoned biopharmaceutical executive with deep expertise in neuropsychopharmacology. He trained at Tufts, Harvard, and Massachusetts General Hospital, later joining the NIH intramural program before moving into industry roles at Johnson & Johnson and Pfizer. Dr. Sporn founded Perception Neuroscience, leading it through the first exit in the psychedelic medicine space to ATAI Life Sciences, where he remains a board member and major shareholder. He is currently Co-Founder and Chief Scientific Officer of Gilgamesh Pharmaceuticals, a Y Combinator-backed company developing next-generation psychedelic therapeutics. In addition, he mentors with the NSF’s I-Corps program and has consulted in digital medicine at Click Therapeutics.
CEO, Gilgamesh